Adrenocortical carcinoma is a rare tumor, and only limited information is available about its natural history and the effects of therapy. We studied 105 patients (75 female and 30 male; mean age, 46 years) with adrenocortical carcinoma who were referred to us between 1963 and 1987. The average duration of symptoms before diagnosis was 8.7 months. At the time of diagnosis, 68 percent of the patients had endocrine symptoms, and 30 percent had distant metastases. Hormonal studies showed that 79 percent of the tumors were functional. Eighty patients underwent surgery, and 59 also received the adrenal cytotoxic agent mitotane. The median disease-free interval after surgery was 12.1 months (range, 1 to 175). Tumor dissemination occurred in 82 percent of the patients, most commonly to the lung, liver, and adjacent organs. The median survival time was 14.5 months (range, less than 1 to 175), and the five-year survival was 22 percent. Age over 40 years and the presence of metastases at the time of diagnosis were the only factors recognized as indicating a poor prognosis. Mitotane controlled hormonal secretion in 75 percent of the patients. Eight mitotane-treated patients had partial tumor regression, but the drug did not have a significant effect on survival. We conclude that adrenocortical carcinoma carries a poor prognosis. Mitotane therapy may offer transient benefits, particularly in controlling endocrine symptoms.
Source Information
Clinique des Maladies Endocriniennes et Metaboliques, Hopital Cochin, Paris, France.
This article has been cited by other articles:
Advani, A, Vaikkakara, S, Gill, M S, Arun, C S, Pearce, S H, Ball, S G, James, R A, Lennard, T W J, Bliss, R D, Quinton, R, Johnson, S J
(2008). Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review. J. Clin. Pathol.
61: 939-944
[Abstract][Full Text]
de Cremoux, P., Rosenberg, D., Goussard, J., Bremont-Weil, C., Tissier, F., Tran-Perennou, C., Groussin, L., Bertagna, X., Bertherat, J., Raffin-Sanson, M.-L.
(2008). Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. Endocr Relat Cancer
15: 465-474
[Abstract][Full Text]
Hermsen, I G C, Gelderblom, H, Kievit, J, Romijn, J A, Haak, H R
(2008). Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.. Eur J Endocrinol
158: 911-919
[Abstract][Full Text]
Bertherat, J., Coste, J., Bertagna, X., Dickstein, G., Shechner, C., Nativ, O., Lee, J. E., Machens, A., Dralle, H., Terzolo, M., Fassnacht, M., Berruti, A.
(2007). Adjuvant Mitotane in Adrenocortical Carcinoma. NEJM
357: 1256-1259
[Full Text]
Carmona-Bayonas, A, Soler, I., Gomez, F., Billalabeitia, E., Saura, H., Tafalla, M., Diaz, M.
(2007). Tailored hormonal therapy in secretory adrenocortical cancer. Ann Oncol
18: 1281-1281
[Full Text]
Delhanty, P. J. D., van Koetsveld, P. M., Gauna, C., van de Zande, B., Vitale, G., Hofland, L. J., van der Lely, A. J.
(2007). Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway. Am. J. Physiol. Endocrinol. Metab.
293: E302-E309
[Abstract][Full Text]
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., Reimondo, G., Bollito, E., Papotti, M., Saeger, W., Hahner, S., Koschker, A.-C., Arvat, E., Ambrosi, B., Loli, P., Lombardi, G., Mannelli, M., Bruzzi, P., Mantero, F., Allolio, B., Dogliotti, L., Berruti, A.
(2007). Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. NEJM
356: 2372-2380
[Abstract][Full Text]
(2007). Image of the Month--Diagnosis. Arch Surg
142: 570-570
[Full Text]
Libe, R., Fratticci, A., Bertherat, J.
(2007). Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer
14: 13-28
[Abstract][Full Text]
Ohwada, S., Izumi, M., Kawate, S., Hamada, K., Toya, H., Togo, N., Horiguchi, J., Koibuchi, Y., Takahashi, T., Yamada, M.
(2007). Surgical Outcome of Stage III and IV Adrenocortical Carcinoma. Jpn J Clin Oncol
0: hyl127v1-6
[Abstract][Full Text]
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., Allolio, B.
(2006). Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab.
91: 4501-4504
[Abstract][Full Text]
Mackie, G. C., Shulkin, B. L., Ribeiro, R. C., Worden, F. P., Gauger, P. G., Mody, R. J., Connolly, L. P., Kunter, G., Rodriguez-Galindo, C., Wallis, J. W., Hurwitz, C. A., Schteingart, D. E.
(2006). Use of [18F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma. J. Clin. Endocrinol. Metab.
91: 2665-2671
[Abstract][Full Text]
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., Bertherat, J.
(2006). Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients. J. Clin. Endocrinol. Metab.
91: 2650-2655
[Abstract][Full Text]
Nader, N., Raverot, G., Emptoz-Bonneton, A., Dechaud, H., Bonnay, M., Baudin, E., Pugeat, M.
(2006). Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans. J. Clin. Endocrinol. Metab.
91: 2165-2170
[Abstract][Full Text]
Allolio, B., Fassnacht, M.
(2006). Adrenocortical Carcinoma: Clinical Update. J. Clin. Endocrinol. Metab.
91: 2027-2037
[Abstract][Full Text]
Slater, E P, Diehl, S M, Langer, P, Samans, B, Ramaswamy, A, Zielke, A, Bartsch, D K
(2006). Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.. Eur J Endocrinol
154: 587-598
[Abstract][Full Text]
Leboulleux, S., Dromain, C., Bonniaud, G., Auperin, A., Caillou, B., Lumbroso, J., Sigal, R., Baudin, E., Schlumberger, M.
(2006). Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography. J. Clin. Endocrinol. Metab.
91: 920-925
[Abstract][Full Text]
Berruti, A., Terzolo, M., Sperone, P., Pia, A., Della Casa, S., Gross, D. J, Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., Reimondo, G., Angeli, A., Dogliotti, L.
(2005). Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer
12: 657-666
[Abstract][Full Text]
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagnere, A.-M., Rene-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., Vacher-Lavenu, M.-C., Perret, C., Bertherat, J.
(2005). Mutations of {beta}-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors. Cancer Res.
65: 7622-7627
[Abstract][Full Text]
Seccia, T. M, Fassina, A., Nussdorfer, G. G, Pessina, A. C, Rossi, G. P.
(2005). Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer
12: 149-159
[Abstract][Full Text]
de Fraipont, F., El Atifi, M., Cherradi, N., Le Moigne, G., Defaye, G., Houlgatte, R., Bertherat, J., Bertagna, X., Plouin, P.-F., Baudin, E., Berger, F., Gicquel, C., Chabre, O., Feige, J.-J.
(2005). Gene Expression Profiling of Human Adrenocortical Tumors Using Complementary Deoxyribonucleic Acid Microarrays Identifies Several Candidate Genes as Markers of Malignancy. J. Clin. Endocrinol. Metab.
90: 1819-1829
[Abstract][Full Text]
Bisceglia, M., Ludovico, O., Di Mattia, A., Ben-Dor, D., Sandbank, J., Pasquinelli, G., Lau, S. K., Weiss, L. M.
(2004). Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature. INT J SURG PATHOL
12: 231-243
[Abstract]
Lefrancois-Martinez, A.-M., Bertherat, J., Val, P., Tournaire, C., Gallo-Payet, N., Hyndman, D., Veyssiere, G., Bertagna, X., Jean, C., Martinez, A.
(2004). Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors. J. Clin. Endocrinol. Metab.
89: 3010-3019
[Abstract][Full Text]
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., Bornstein, S. R.
(2004). The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management. Endocr. Rev.
25: 309-340
[Abstract][Full Text]
Ng, W T, Toohey, M G, Mulhall, L, Mackey, D A
(2003). Pigmentary retinopathy, macular oedema, and abnormal ERG with mitotane treatment. Br. J. Ophthalmol.
87
: 500-501
[Full Text]
Groussin, L., Jullian, E., Perlemoine, K., Louvel, A., Leheup, B., Luton, J. P., Bertagna, X., Bertherat, J.
(2002). Mutations of the PRKAR1A Gene in Cushing's Syndrome due to Sporadic Primary Pigmented Nodular Adrenocortical Disease. J. Clin. Endocrinol. Metab.
87: 4324-4329
[Abstract][Full Text]
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M., Cordon-Cardo, C., Jaques, D. P., Brennan, M. F.
(2002). Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization. JCO
20: 941-950
[Abstract][Full Text]
Gicquel, C., Bertagna, X., Gaston, V., Coste, J., Louvel, A., Baudin, E., Bertherat, J., Chapuis, Y., Duclos, J.-M., Schlumberger, M., Plouin, P.-F., Luton, J.-P., Le Bouc, Y.
(2001). Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors. Cancer Res.
61: 6762-6767
[Abstract][Full Text]
Martinerie, C., Gicquel, C., Louvel, A., Laurent, M., Schofield, P. N., Le Bouc, Y.
(2001). Altered Expression of novH Is Associated with Human Adrenocortical Tumorigenesis. J. Clin. Endocrinol. Metab.
86: 3929-3940
[Abstract][Full Text]
Kendrick, M. L., Lloyd, R., Erickson, L., Farley, D. R., Grant, C. S., Thompson, G. B., Rowland, C., Young, W. F. Jr, van Heerden, J. A.
(2001). Adrenocortical Carcinoma: Surgical Progress or Status Quo?. Arch Surg
136: 543-549
[Abstract][Full Text]
de Fraipont, F., El Atifi, M., Gicquel, C., Bertagna, X., Chambaz, E. M., Feige, J. J.
(2000). Expression of the Angiogenesis Markers Vascular Endothelial Growth Factor-A, Thrombospondin-1, and Platelet-Derived Endothelial Cell Growth Factor in Human Sporadic Adrenocortical Tumors: Correlation with Genotypic Alterations. J. Clin. Endocrinol. Metab.
85: 4734-4741
[Abstract][Full Text]
Terzolo, M., Pia, A., Berruti, A., Osella, G., Alì, A., Carbone, V., Testa, E., Dogliotti, L., Angeli, A.
(2000). Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer. J. Clin. Endocrinol. Metab.
85: 2234-2238
[Abstract][Full Text]
Hayes, F. J., Eichhorn, J. H.
(2000). Case 12-2000- A 60-Year-Old Man with Persistent Gynecomastia after Excision of a Pituitary Adenoma. NEJM
342: 1196-1204
[Full Text]
Mantero, F., Terzolo, M., Arnaldi, G., Osella, G., Masini, A. M., Alì, A., Giovagnetti, M., Opocher, G., Angeli, A.
(2000). A Survey on Adrenal Incidentaloma in Italy. J. Clin. Endocrinol. Metab.
85: 637-644
[Abstract][Full Text]
Bourcigaux, N., Gaston, V., Logié, A., Bertagna, X., Le Bouc, Y., Gicquel, C.
(2000). High Expression of Cyclin E and G1 CDK and Loss of Function of p57KIP2 Are Involved in Proliferation of Malignant Sporadic Adrenocortical Tumors. J. Clin. Endocrinol. Metab.
85: 322-330
[Abstract][Full Text]
(1999). Adrenal Hyperandrogenism in Children. J. Clin. Endocrinol. Metab.
84: 4431-4435
[Full Text]
Bornstein, S. R., Stratakis, C. A., Chrousos, G. P.
(1999). Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management. ANN INTERN MED
130: 759-771
[Abstract][Full Text]
Barzon, L., Fallo, F., Sonino, N.
(1999). Comment--Is There a Role for Low Doses of Mitotane (o,p'-DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?. J. Clin. Endocrinol. Metab.
84: 1488-1488
[Full Text]
Harrison, L. E., Gaudin, P. B., Brennan, M. F.
(1999). Pathologic Features of Prognostic Significance for Adrenocortical Carcinoma After Curative Resection. Arch Surg
134: 181-185
[Abstract][Full Text]
Dickstein, G., Shechner, C., Arad, E., Best, L.-A., Nativ, O.
(1998). Is There a Role for Low Doses of Mitotane (o,p'-DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?. J. Clin. Endocrinol. Metab.
83: 3100-3103
[Abstract][Full Text]
Gicquel, C., Raffin-Sanson, M.-L., Gaston, V., Bertagna, X., Plouin, P.-F., Schlumberger, M., Louvel, A., Luton, J.-P., Le Bouc, Y.
(1997). Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors. J. Clin. Endocrinol. Metab.
82: 2559-2565
[Abstract][Full Text]
Latronico, A. C., Chrousos, G. P.
(1997). Adrenocortical Tumors. J. Clin. Endocrinol. Metab.
82: 1317-1324
[Full Text]
Previous
